Pouessel Damien, Culine Stephane, Becht Catherine, Romieu Gilles, Fabbro Michel, Ychou Marc, Cupissol Didier, Pinguet Frederic
Centre Régional de Lutte contre le Cancer Val d'Aurelle Montpellier, Parc Euromédecine, 34298-Montpellier, France.
Anticancer Res. 2003 May-Jun;23(3C):2801-4.
The prognosis of patients with carcinoma of unknown primary remains poor with an expected median survival of 6 to 12 months. We evaluated the activity of a chemotherapy regimen combining gemcitabine and docetaxel in patients who primarily failed cisplatin-based chemotherapy.
Fifteen patients received cycles of gemcitabine 1,000 mg/m2 on days 1 and 8 and docetaxel 75 mg/m2 on day 8 every 3 weeks.
The median number of cycles per patient was 3. Overall toxicity was moderate. Four partial responses were observed among 14 patients with measurable disease. The median survival was 8 months from start of therapy and 23 months from diagnosis.
These results were obtained in a small series of selected patients and require further confirmation in the front-line management of the disease.
原发灶不明癌患者的预后仍然很差，预期中位生存期为6至12个月。我们评估了吉西他滨和多西他赛联合化疗方案对主要接受过以顺铂为基础化疗但治疗失败患者的疗效。
15例患者每3周接受一个疗程的治疗，第1天和第8天给予吉西他滨1000mg/m²，第8天给予多西他赛75mg/m²。
每位患者的中位疗程数为3个。总体毒性为中度。在14例可测量疾病的患者中观察到4例部分缓解。从治疗开始的中位生存期为8个月，从诊断开始为23个月。
这些结果是在一小部分选定的患者中获得的，需要在该疾病的一线治疗中进一步证实。
